## Amendment Tool

v1.4 30 Nov 2020

| Short project title*:   | Perioprative quality i   | mprovement progra | mme: Patient study | /             |                 |  |  |  |  |  |  |
|---|--|-------------------|--------------------|---------------|-----------------|--|--|--|--|--|--|
| IRAS project ID* (or REC reference if no IRAS project ID is available):   | 215928   |                   |                    |               |                 |  |  |  |  |  |  |
| Sponsor amendment reference number*:  | Non-Substantial Am   | ndment 19         |                    |               |                 |  |  |  |  |  |  |
| Sponsor amendment date* (enter as DD/MM/YY):  |  |                   |                    |               |                 |  |  |  |  |  |  |
| Briefly summarise in lay language the main changes<br>proposed in this amendment. Explain the purpose of the<br>changes and their significance for the study. If the<br>amendment significantly alters the research design or<br>methodology, or could otherwise affect the scientific value<br>of the study, supporting scientific information should be<br>given (or enclosed separately). Indicate whether or not<br>additional scientific critique has been obtained (note: this<br>field will adapt to the amount of text entered)*: | We are requesting changes to some of the case report form questions, including deleting several questions, adding question, and modifying questions. |                   |                    |               |                 |  |  |  |  |  |  |
|   |  |                   | Specific study     |               |                 |  |  |  |  |  |  |
| Project type (select):  |  | o                 | Research tissu     | ie bank       |                 |  |  |  |  |  |  |
|   | o Research database  |                   |                    |               |                 |  |  |  |  |  |  |
| Has the study been reviewed by a UKECA-recognised Rese<br>Committee (REC) prior to this amendment?:   | ٠  | Yes               | o                  | No            |                 |  |  |  |  |  |  |
|   |  | NHS/HSC REC       |                    |               |                 |  |  |  |  |  |  |
| What type of UKECA-recognised Research Ethics Committe<br>is applicable? (select):  | ee (REC) leview  | o                 | Ministry of Def    | ence (MoDREC) |                 |  |  |  |  |  |  |
| Is all or part of this amendment being resubmitted to the Res<br>Committee (REC) as a <b>modified amendment</b> (i.e. a substate<br>previously given an unfavourable opinion)?  |  | o                 | Yes                | 6             | No              |  |  |  |  |  |  |
| Where is the NHS/HSC Research Ethics Committee (REC)  | that reviewed the  | England           | Wales              | Scotland      | Northern Irelar |  |  |  |  |  |  |
| study based?:   |  |                   | 0                  | 0             | 0               |  |  |  |  |  |  |
| Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:  | product (CTIMP)  | 0                 | Yes                | 8             | No              |  |  |  |  |  |  |
| Was the study a clinical investigation or other study of a med<br>does the amendment make it one?:  | dical device OR  | 0                 | Yes                |               | No              |  |  |  |  |  |  |
| Did the study involve the administration of radioactive substa<br>requiring ARSAC review, OR does the amendment introduce   |  | o                 | Yes                | 8             | No              |  |  |  |  |  |  |
| Did the study involve the use of research exposures to ionisi involving the administration of radioactive substances) OR d amendment introduce this?:   |  | o                 | Yes                | ® No          |                 |  |  |  |  |  |  |
| Did the study involve adults lacking capacity OR does the ar introduce this?:   | mendment   | 0                 | Yes                | 8             | No              |  |  |  |  |  |  |
| Did the study involve access to confidential patient informati direct care team without consent OR does the amendment in  |  | o                 | Yes                | Ø             | No              |  |  |  |  |  |  |
| Did the study involve prisoners OR does the amendment inter   | roduce this?:  | 0                 | Yes                | No            |                 |  |  |  |  |  |  |
| Did the study involve NHS/HSC organisations prior to this a   |  |                   | Yes                | o No          |                 |  |  |  |  |  |  |
| Did the study involve non-NHS/HSC organisations OR does introduce them?:  | the amendment  | ۲                 | Yes                | 0             | No              |  |  |  |  |  |  |
|   |  | England           | Wales              | Scotland      | Northern Irelar |  |  |  |  |  |  |
| Lead nation for the study:  |  | ۲                 | o                  | 0             | o               |  |  |  |  |  |  |
| Which nations had participating NHS/HSC organisations price amendment?  |  | V                 | V                  | Ø             | V               |  |  |  |  |  |  |
| Which nations will have participating NHS/HSC organisation amendment?   | ns after this  | V                 | V                  | Ø             | Ø               |  |  |  |  |  |  |
| Which nations had participating non-NHS/HSC organisation: amendment?  | s prior to this  | Ø                 | Ø                  | Ø             | Ø               |  |  |  |  |  |  |
| Which nations will have participating non-NHS/HSC organis   | ations after this  |                   | V                  | Ø             | V               |  |  |  |  |  |  |

## Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the amendment tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, tick the "Add another change" box.

|  | Change 1  |       |          |                  |        |  |  |  |  |  |
|--|---|-------|----------|------------------|--------|--|--|--|--|--|
| Area of change (select)*:  | Study Documents   |       |          |                  |        |  |  |  |  |  |
| Specific change (select - only available when area of<br>change is selected first)*:   | o study documents (e.g. information sheets, consent forms, questionnaire<br>plemented within existing resource in place at participating organisations<br>free text below |       |          |                  |        |  |  |  |  |  |
| Further information (free text - note that this field will adapt to the amount of text entered):   | Changes made to patient questionnaires to clarify ethnicity, socioeconomic data and to reduce data collection burden for patients (i.e. some questions removed)           |       |          |                  |        |  |  |  |  |  |
| Applicability:   | England   | Wales | Scotland | Northern Ireland |        |  |  |  |  |  |
| Where are the participating NHS/HSC organisations located this change?*:   | V   | V     | Ø        | V                |        |  |  |  |  |  |
| Will all participating NHS/HSC organisations be affected by some? ( <b>please note</b> that this answer may affect the categories of the source of t | ¢   | All   | ○ Some   |                  |        |  |  |  |  |  |
| Where are the participating non-NHS/HSC organisations loo<br>affected by this change?*:  | Ø   | Ø     | Ø        | Ø                |        |  |  |  |  |  |
|  |   | •     | •        | Add another char | nge: ⊠ |  |  |  |  |  |

|  | Change 2                   |                     |                       |          |                  |  |  |  |  |  |  |
|--|----------------------------|---------------------|-----------------------|----------|------------------|--|--|--|--|--|--|
| Area of change (select)*:  | Participating Organisa     | sations             |                       |          |                  |  |  |  |  |  |  |
| Specific change (select - only available when area of<br>change is selected first)*:   | Addition of sites under    | rtaking the same a  | ctivities as existing | sites    |                  |  |  |  |  |  |  |
| Further information (free text - note that this field will adapt to the amount of text entered):                                 | Addition of Chesterfiel    | ld Royal Hospital N | IHS Foundation Tr     | ust      |                  |  |  |  |  |  |  |
| Applicability:   |                            | England             | Wales                 | Scotland | Northern Ireland |  |  |  |  |  |  |
| Where are the participating NHS/HSC organisations located this change?*:   | d that will be affected by | Ø                   | Ŋ                     | V        | Ø                |  |  |  |  |  |  |
| Will all participating NHS/HSC organisations be affected by<br>some? ( <b>please note</b> that this answer may affect the catego | 0,                         |                     | All                   | o        | Some             |  |  |  |  |  |  |
| Where are the participating non-NHS/HSC organisations loo<br>affected by this change?*:  | cated that will be         | V                   | V                     | V        |                  |  |  |  |  |  |  |

Add another change:

| Change 3  |  |  |          |                  |        |  |  |  |  |  |
|---|--|--|----------|------------------|--------|--|--|--|--|--|
| Area of change (select)*:   | Researchers  |  |          |                  |        |  |  |  |  |  |
| Specific change (select - only available when area of<br>change is selected first)*:                                      | PI - New PI, or tempor                                 | rary arrangements to cover the absence of a PI |          |                  |        |  |  |  |  |  |
| Further information (free text - note that this field will adapt to the amount of text entered):                          | New PI at Medway NHS Foundation Trust - Dr Rachel Krol |  |          |                  |        |  |  |  |  |  |
| Applicability:  | England  | Wales  | Scotland | Northern Ireland |        |  |  |  |  |  |
| Where are the participating NHS/HSC organisations located this change?*:  | Ŋ  | Ø  | V        | Ø                |        |  |  |  |  |  |
| Will all participating NHS/HSC organisations be affected by<br>some? (please note that this answer may affect the categor | \$   | All  | ° Some   |                  |        |  |  |  |  |  |
| Where are the participating non-NHS/HSC organisations loo<br>affected by this change?*:                                   | Ø  | Ø  | Ø        | Ø                |        |  |  |  |  |  |
|   |  |  |          | Add another cha  | nge: 🗆 |  |  |  |  |  |

| Declaration by the Sponsor or authoris | ed delegate   |
|--|---|
|  | sibility for the completed amendment tool<br>orised by the Sponsor to complete the amendment tool on their behalf |
| Name [first name and surname]*:        | Pushpsen Joshi  |
| Email address*:                        | pushpsen.joshi1@nhs.net   |
| Lock for submission                    |   |
|  |   |

Lock for submission

## Section 4: Review bodies for the amendment

|                                |          |   |                                       |         |                     |                 |           | F      | Review | bodie                 | S      |      |                   |                                |     |                  |         |                                |         |
|--------------------------------|----------|---|---------------------------------------|---------|---------------------|-----------------|-----------|--------|--------|-----------------------|--------|------|-------------------|--------------------------------|-----|------------------|---------|--------------------------------|---------|
|                                | UK wide: |   |                                       |         | Eng                 | land a          | nd Wa     | ales:  |        | Scotland:             |        |      | Northern Ireland: |                                |     |                  |         |                                |         |
|                                |          | Competent Authority<br>MHRA - Medicines | Competent Authority<br>MHRA - Devices | ARSAC   | Radiation Assurance | UKSW Governance | REC (MCA) | (1)    | SddWH  | HRA and HCRW Approval | (AWIA) | d    | (RAEC)            | National coordinating function | REC | ) Data Guardians | Prisons | National coordinating function |         |
|                                | REC      | Comp<br>MHR/                            | Compe<br>MHRA                         | ARS     | Rad                 | NKS             | REC       | CAG    | HMF    | HRA                   | REC    | РВРР | SPS               |                                | HSC | HSC              | Pris    |                                | Categor |
| Change 1:                      |          |   |                                       |         |                     | (Y)             |           |        |        | (Y)                   |        |      |                   | (Y)                            |     |                  |         | (Y)                            | С       |
| Change 2:                      |          |   |                                       |         |                     | (Y)             |           |        |        | (Y)                   |        |      |                   | (Y)                            |     |                  |         | (Y)                            | New sit |
| Change 3:                      |          |   |                                       |         |                     | (Y)             |           |        |        | (Y)                   |        |      |                   | (Y)                            |     |                  |         | (Y)                            | А       |
| Overall reviews for the amendr | nent:    |   |                                       |         |                     |                 |           |        |        |                       |        |      |                   |                                |     |                  |         |                                |         |
| Full review:                   |          |   |                                       |         |                     | Ν               |           |        |        | Ν                     |        |      |                   | Ν                              |     |                  |         | Ν                              |         |
| Notification only:             |          |   |                                       |         |                     | Y               |           |        |        | Y                     |        |      |                   | Y                              |     |                  |         | Y                              |         |
| Overall amendment type:        | No       | n-subs                                  | stantial                              | l, no s | udy-w               | ide rev         | view re   | quired |        | -                     |        |      |                   | -                              |     |                  |         |                                |         |
| Overall Category:              | Α        |   |                                       |         |                     |                 |           |        |        |                       |        |      |                   |                                |     |                  |         |                                |         |